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Cocrystals	of	Spironolactone	and	Griseofulvin	Based	on	an	in	Silico	
Screening	Method	
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Cocrystal	formation	is	considered	as	one	of	the	most	effective	solid-state	methods	to	alter	the	physicochemical	properties	
of	active	pharmaceutical	 ingredients	(APIs).	 In	silico	methods	for	cocrystal	prediction	are	mostly	based	on	structural	and	
energetic	considerations.	We	have	developed	a	computational	method	that	ranks	the	probability	of	cocrystal	formation	of	
APIs	with	 large	databases	of	 crystal	 coformers	 (CCFs).	This	approach	 is	based	on	using	molecular	electrostatic	potential	
surfaces	to	assess	molecular	complementarity	between	two	cocrystal	components.	The	screening	tool	was	applied	to	two	
low	 solubility	 drugs,	 namely	 griseofulvin	 and	 spironolactone.	 Promising	 coformer	 candidates	 were	 selected	 from	 a	
database	of	310	pharmaceutically	acceptable	CCFs,	and	experimental	screening	was	carried	out.	Novel	solid	forms	were	
obtained	by	liquid-assisted	grinding	and	were	characterised	by	XRPD,	DSC,	TGA	and	IR.	One	new	cocrystal	of	griseofulvin	
and	 two	 new	 cocrystals	 of	 spironolactone	were	 identified,	 and	 the	 crystal	 structures	were	 determined	 from	 the	 XRPD	
patterns.	For	these	systems,	phenols	tend	to	act	as	successful	H-bond	donors	in	forming	cocrystals,	while	carboxylic	acids	
only	give	rise	to	physical	mixtures	of	the	two	components.	
Introduction	
The	exploration	of	active	pharmaceutical	ingredient	(API)	solid	
state	 chemistry	 is	 an	 integral	 part	 of	 drug	 discovery	 and	
pharmaceutical	 development.1	 Solubility	 properties	 and	 the	
dissolution	rate	of	a	solid	drug	are	key	parameters	in	dictating	
oral	bioavailability.2	With	the	use	of	high-throughput	screening	
methodology	 and	 combinatorial	 chemistry,	 the	 number	 of	
poorly	 soluble	 APIs	 has	 risen	 dramatically.3	 Drugs	 exhibiting	
poor	 bioavailability	 are	 categorised	 as	 Biopharmaceutical	
Classification	System	(BCS)	class	II	and	class	IV,	based	on	their	
low	 solubility	 properties.4	 Several	 approaches	 in	 drug	
formulation	have	been	designed	to	improve	drug	solubilisation	
in	the	gastrointestinal	 tract.	Non-covalent	approaches	 include	
the	 use	 of	 cyclodextrin	 inclusion	 compounds,5	 solid	
dispersions,6	 amorphous	 forms7	 as	well	 as	 salt8	 and	 cocrystal	
formation.9	
Pharmaceutical	 cocrystals	 are	 molecular	 adducts	 of	 definite	
stoichiometry	where	one	component	 is	a	neutral	API	and	 the	
other	 is	 a	 neutral	 pharmaceutically	 acceptable	 crystal	
coformer	 (CCF)	 and	 both	 components	 are	 solids	 at	 room	
temperature.10	 The	 CCFs	 are	 usually	 selected	 from	 the	 GRAS	
(Generally	 Regarded	 as	 Safe)11	 and	 EAFUS	 (Everything	 Added	
to	 Food	 in	 the	United	States)12	 lists	 if	 the	 resulting	 cocrystals	
are	 to	 be	 considered	 suitable	 for	 drug	 development.	 The	
benefit	of	cocrystallisation	is	that	non-ionisable	API	molecules	
can	 also	 be	 targeted,	 so	 the	 list	 of	 potential	 CCFs	 is	 more	
comprehensive	 than	 for	 salt	 formation.	 In	 recent	 years,	 the	
exploration	 of	 pharmaceutical	 cocrystals	 has	 led	 to	 the	
successful	enhancement	of	physicochemical	properties	of	APIs,	
such	 as	 thermal,	 humidity	 and	 thermodynamic	 stability.13	
Other	 important	 pharmaceutical	 properties	 that	 have	 been	
improved	through	cocrystal	formation	are	clinical	performance	
and	manufacturability.14	
In	 2013,	 the	 FDA	 considered	 cocrystals	 as	 ‘API-excipient’	
complexes	that	were	treated	as	drug	product	intermediates.15	
The	 new	 2016	 FDA	 draft	 guidance	 explains	 that	 cocrystals	
should	 be	 classified	 as	 special	 cases	 of	 solvates,	 where	 the	
second	 component	 is	 non-volatile.16	 From	 a	 regulatory	
perspective,	 a	 cocrystal	will	 be	 treated	 in	 the	 same	way	 as	 a	
new	 polymorph	 of	 the	 same	 API	 and	 not	 as	 a	 different	
chemical	entity,	as	 is	the	case	for	salts.	The	new	classification	
has	 consequences	 for	 the	 development	 of	 cocrystals	 in	 the	
pharmaceutical	 industry	 due	 to	 the	 simplification	 of	 the	
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multicomponent	 complex	 regulatory	 landscape.	 For	 example,	
it	 will	 be	 possible	 to	 use	 existing	 regulatory	 documents	 to	
establish	potency,	purity	and	stability	of	a	cocrystal	API.17	
The	 process	 of	 cocrystal	 screening	 can	 generally	 be	 broken	
down	 into	 sample	 preparation,	 characterisation	 and	
determination	 of	 properties.18	 Conventional	 experimental	
cocrystal	 screens	 employed	 are	 solution	 based,	 such	 as	 slow	
evaporation,	 cooling	 and	 vapour	 diffusion.19	 These	 methods	
are	 useful	 as	 they	 can	 yield	 suitable	 crystals	 for	 structure	
determination	 by	 single	 crystal	 X-ray	 diffraction.	 However,	
single	crystal	growth	is	inherently	slow	and	there	is	a	high	risk	
of	 hydrates	 and	 solvates	 being	 formed.20	 Furthermore	 if	 the	
solubilities	of	the	API	and	CCF	are	very	different,	precipitation	
of	 the	 least	 soluble	 component	 is	 more	 likely	 to	 take	 place	
rather	 than	 the	 desired	 cocrystal.21	 Neat	 grinding	 (NG)	 and	
liquid-assisted	 grinding	 (LAG)	 experiments	were	 shown	 to	 be	
more	 efficient	 at	 identifying	 cocrystals	 as	 they	 avoid	 solvent	
competition	 that	 can	 lead	 to	 precipitation	 of	 individual	
components.22	Moreover,	advances	in	powder	X-ray	diffraction	
methods	mean	that	crystal	structure	solutions	can	be	obtained	
from	powder	data	with	good	accuracy.23	
In	this	work,	we	apply	a	virtual	cocrystal	screening	method24	to	
two	 BCS	 class	 II	 APIs,	 griseofulvin	 (GSF)	 and	 spironolactone	
(SPN).25-27	The	 in	 silico	 screening	method	has	been	previously	
validated	 using	 experimental	 cocrystal	 data	 reported	 in	 the	
literature28	and	was	successfully	applied	to	obtain	seven	novel	
cocrystals	of	nalidixic	acid.29	This	methodology	is	not	limited	to	
cocrystal	prediction.	It	can	be	applied	to	formation	of	ionizable	
multi-component	adducts	such	as	salts	and	propensity	to	form	
solvates	 for	 a	 specific	 API.	 The	 computational	 approach	 uses	
calculated	molecular	electrostatic	potential	surfaces	(MEPS)	to	
identify	surface	site	 interaction	points	 (SSIPs).24	The	SSIPs	can	
be	used	to	assess	the	molecular	recognition	properties	of	the	
entire	 surface	 of	 the	molecule,30	 and	 here,	 they	 are	 used	 to	
calculate	 the	 solid	 state	 interaction	 site	 pairing	 energy,	 E,	
defined	 in	 Equation	 1,	which	 is	 the	 sum	of	 all	 intermolecular	
interactions	 in	 a	 solid.	 The	 SSIPs	 of	 a	 molecule	 are	 each	
described	by	an	interaction	parameter,	εi,	which	is	positive	for	
a	 H-bond	 donor	 site	 (or	 positive	 region	 on	 the	 MEPS)	 and	
negative	for	a	H-bond	acceptor	site	(or	negative	region	on	the	
MEPS).	The	energy	of	interaction	between	two	SSIPs,	i	and	j,	is	
given	by	the	product	εiεj.	The	stability	of	a	solid	is	estimated	by	
a	hierarchical	pairing	of	charge-complementary	SSIPs	to	obtain	
E:	the	most	positive	SSIP	pairs	the	most	negative	SSIP,	followed	
by	 sequential	 association	 of	 the	 second	 most	 positive	 and	
negative	 SSIPs	 until	 no	 more	 pairwise	 interactions	 can	 be	
formed.31	𝐸 = 𝜀!𝜀!!"   Eq. 1 
The	 difference	 in	 the	 pairing	 energy	 between	 the	 pure	
components	and	the	cocrystal	(ΔE)	provides	a	measure	of	the	
probability	of	forming	a	cocrystal	(eq.	2):	∆𝐸 = − 𝐸!! − 𝐸! − 𝐸!   Eq. 2 
where	Ecc,	E1	and	E2	are	the	interaction	site	pairing	energies	of	
the	cocrystal	and	the	pure	solids,	1	and	2,	respectively.	
Validation	of	the	ΔE	parameter	was	recently	provided	by	a	CCF	
exchange	 experiment	 using	 caffeine	 cocrystals.32	 The	
experiment	 involved	grinding	multiple	CCFs	with	caffeine	and	
using	 the	 identities	 of	 the	 cocrystals	 that	 formed	 in	 the	
mixtures	 to	 establish	 a	 cocrystal	 stability	 ranking.	 The	
experimental	 stability	 ranking	 for	 the	 caffeine	 cocrystals	
matched	the	previously	published	ranking	of	ΔE	values.24	
GSF	is	an	antifungal	BCS	class	II	drug	that	has	been	reported	to	
exhibit	 antiviral	 and	 anticancer	 effects	 in	 mammalian	
systems.33	An	enhancement	in	GSF	bioavailability	was	obtained	
by	 nanoparticle	 preparation	 from	 water-dilutable	
microemulsions,34	 the	 use	 of	 drug-polymer	 solid	 solutions35	
and	nanocapsules.36	In	a	cocrystal	screen,	grinding	of	GSF	with	
40	 coformers	 only	 yielded	 a	 2:1	 GSF-acesulfame	 cocrystal	
hydrate,	where	the	two	cocrystal	components	interact	via	the	
water	 molecule.25	 The	 screen	 also	 yielded	 GSF	 solvates	 with	
acetonitrile,	nitromethane	and	nitroethane.37	More	recently,	a	
drug-polymer	 cocrystal	 was	 reported	 between	 GSF	 and	
polyethylene	glycol.38	
SPN	has	been	extensively	used	as	a	potassium-sparing	diuretic.	
It	 is	 a	 non-ionisable	 BCS	 class	 II	 drug	 that	 acts	 as	 a	 steroidal	
aldosterone	 antagonist.39	 Improvement	 in	 SPN	 biovailability	
was	 obtained	 by	 nanosuspension	 formulation,40	 drug	
micronization	 and	 the	 use	 of	 β-cyclodextrins.41	 In	 the	
literature,	 there	 are	 also	 two	 studies	 concerned	 with	 the	
cocrystallisation	 of	 SPN.	 A	 1:1	 SPN-saccharin	 cocrystal	
hemihydrate	 has	 been	 reported,	 where	 crystal	 packing	
remained	 largely	unchanged	after	dehydration.26	 In	a	 cocktail	
grinding	study,	several	CCFs	were	ground	simultaneously	with	
SPN,27	and	novel	powder	patterns	were	obtained	with	benzoic,	
salicylic	and	gentisic	acid.	
Here	we	describe	the	structures	of	new	cocrystals	of	both	GSF	
and	 SPN	 that	 were	 obtained	 after	 in	 silico	 screening	 of	 a	
database	of	310	pharmaceutically	acceptable	CCFs.	
Experimental	
Virtual	cocrystal	screen:	Molecular	structures	of	GSF,	SPN	and	
all	 310	 CCFs	were	 drawn	 in	 an	 extended	 conformation	 using	
the	 TorchLite	 software,42	 so	 that	 the	 functional	 groups	 were	
exposed	 and	 available	 for	 interaction.	 The	 structures	 were	
energy	minimised	 using	 the	 XED3	 force	 field	 implemented	 in	
TorchLite,	and	the	MEPS	were	calculated	using	DFT	 (B3LYP	6-
31G*)	in	Gaussian	09.43	The	MEPS	were	then	converted	into	a	
set	 of	 SSIPs	 using	 the	 method	 described	 previously.27b	 The	
increase	 in	 stability	of	 the	1:1	cocrystal	 compared	 to	 the	 two	
pure	components	was	estimated	for	all	CCF-GSF	and	CCF-SPN	
combinations	 based	 on	 the	 difference	 in	 the	 interaction	 site	
pairing	energies,	ΔE,	calculated	using	Equations	1	and	2	above.	
Materials:	 GSF,	 SPN,	 all	 selected	 CCFs	 and	 solvents	 were	
purchased	from	Sigma-Aldrich	and	used	as	received.	
Grinding:	 Grinding	 experiments	 were	 performed	 by	 mixing	
stoichiometric	amounts	of	GSF	and	SPN	(20	mg)	with	CCFs	in	a	
5	mL	stainless	steel	grinding	jar	containing	a	grinding	ball	7	mm	
in	 diameter.	 In	 LAG	 experiments,	 15	 µl	 of	 acetonitrile	 or	 n-
heptane	 was	 also	 added.	 Neat	 grinding	 was	 carried	 out	 for	
some	systems	where	the	coformers	were	highly	soluble	or	had	
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low	 melting	 points:	 phenol,	 4-tert-butylphenol,	 2-phenyl	
phenol,	 indole,	 skatole	 and	 xylenols.	 The	 mixtures	 were	
ground	on	a	Retsch	MM	200	mixer	mill	for	20	to	45	minutes	at	
30	Hz.	
X-ray	 Powder	 Diffraction	 (XRPD)	 Measurements:	 Powder	
samples	were	mounted	on	a	silicon	wafer	mount	and	analyzed	
on	a	PANalytical	CubiX	PRO	diffractometer	with	a	copper	long-
fine	 focus	 tube	 running	 at	 45	 kV	 and	 40	mA	 (λ	 =	 1.5418	 Å).	
Samples	 were	 measured	 in	 reflection	 geometry	 in	 the	 θ–2θ	
configuration	 over	 a	 scan	 range	 from	2°	 to	 40°	 2θ	with	 1.9	 s	
exposure	per	0.0025°	increment.	
Infrared	 Spectroscopy	 (IR):	 IR	 spectra	 were	 recorded	 with	 a	
universal	ATR	sampling	accessory	on	a	Perkin-Elmer	Spectrum	
100	 Fourier	 transform	 spectrophotometer	 over	 a	 range	 from	
400	to	4000	cm–1	with	a	resolution	of	1	cm–1	(eight	scans).	The	
spectra	 were	 processed	 with	 the	 Spectrum	 v	 10.03.07	
software.	
Differential	 Scanning	 Calorimetry	 (DSC):	 DSC	 measurements	
were	 performed	 using	 a	 Discovery	 DSC	 calorimeter.	 About	 3	
mg	of	solid	material	was	weighed	into	a	T0	aluminium	pan	that	
was	sealed	hermetically	with	an	aluminium	 lid.	Samples	were	
equilibrated	 at	 25°C	 and	 then	 heated	 to	 225°C	 or	 235°C	 at	 a	
rate	of	10°C	min–1.	
Thermogravimetric	 analysis	 (TGA):	 TGA	measurements	 were	
performed	 on	 a	 TA	 Q5000	 instrument.	 An	 open	 alumina	
crucible	 was	 used	 to	 heat	 the	 sample	 from	 25°C	 to	 the	
required	 temperature	at	a	 rate	of	10°C/min	under	a	nitrogen	
stream.	
XRPD	structure	determination:	For	the	GSF-4-tert-butylphenol	
cocrystal,	 a	 Panalytical	 X’Pert	 PRO	 MPD	 instrument	 with	
capillary	 configuration	 in	 transmission	 geometry,	 focusing	
elliptic	 mirror	 and	 PIXcel	 detector	 working	 at	 a	 maximum	
detector	active	length	of	3.347º	2θ,	was	used.	CuKα	radiation	(λ	
=	1.5418	Å)	was	selected	with	focalizing	0.01	and	0.02	radians	
Soller	slits.	The	instrument	was	operated	at	45	kV	and	40	mA.	
Samples	were	placed	in	Lindemann	capillaries	of	diameter	0.7	
mm	and	were	measured	from	2°	to	70°	2θ,	with	a	step	size	of	
0.013°	 and	 a	 data	 collection	 time	 of	 16	 hrs.	 The	 powder	
pattern	 was	 indexed	 to	 a	 monoclinic	 cell	 of	 approximate	
volume	1302	Å3	by	means	of	Dicvol0444	 and	 the	 space	group	
was	 determined	 to	 be	 P21	 from	 the	 systematic	 absences.	
Based	on	the	calculated	density,	 it	was	established	that	 there	
was	 one	 independent	molecule	 of	 GSF	 and	 one	 independent	
molecule	 of	 4-tert-butylphenol	 in	 the	 asymmetric	 unit.	 The	
crystal	 structure	 was	 determined	 by	 direct	 space	
methodologies	 starting	 from	 a	 molecular	 model	 optimized	
with	 the	 commercial	 software	 SPARTAN	 by	 means	 of	 the	
program	 FOX45	 with	 the	 parallel	 tempering	 algorithm.	
Constraints	on	molecular	geometry	were	applied,	in	particular	
considering	aromatic	rings	as	rigid	groups.	Several	 trials	of	20	
million	runs	were	performed.	Refinement	of	the	structure	was	
performed	 by	 the	 Rietveld	 method50	 using	 FullProf46	 and	
converged	 to	 χ2	 =	 6.212.	 Figure	 S1	 of	 the	 supplementary	
information	depicts	the	final	Rietveld	plot.	
For	 the	 SPN-phenol	 and	 SPN-2,5-xylenol	 cocrystals,	 solid	
samples	were	 loaded	 into	a	0.7	mm	borosilicate	capillary.	 	X-
ray	diffraction	data	were	collected	(λ	=	0.82665	Å)	at	beamline	
I11	 at	 Diamond	 Light	 Source,47	 using	 a	 wide	 angle	 (90°)	 PSD	
detector	comprising	multiple	Mythen-2	modules.	Five	pairs	of	
five-second	 scans	 were	 conducted	 at	 room	 temperature,	
related	by	a	0.25°	detector	offset	to	account	for	gaps	between	
detector	modules,	in	addition	to	two	pairs	of	one-second	scans	
before	 and	 afterwards,	 to	 check	 for	 beam	 damage	 to	 the	
sample.	 All	 resulting	 patterns	were	 summed	 to	 give	 the	 final	
pattern	 for	 structural	 analysis.	 Both	 powder	 patterns	 were	
indexed	to	a	single	phase	using	the	TOPAS	program.48	The	new	
unit	 cells	 were	 then	 fitted	 using	 single-phase	 Pawley	
refinements.49	SPN-phenol	crystallised	in	an	orthorhombic	unit	
cell	 and	SPN-2,5-xylenol	 in	a	monoclinic	unit	 cell.	 These	were	
compared	 with	 existing	 crystal	 structures	 for	 SPN	 and	 the	
corresponding	 CCF	 in	 the	 CCDC,	 already	 established	 from	
single-crystal	X-ray	diffraction.	No	match	with	any	single	phase	
or	mixture	 of	 the	 two	 phases	was	 found.	 The	 starting	model	
used	 for	 the	 Rietveld	 refinement,50	 conducted	 using	 TOPAS,	
was	rigid-body	models	 (represented	as	z-matrices)	of	 the	two	
cocrystal	 pure	 components	 from	 the	 single-crystal	 structures.	
These	 rigid	 bodies	were	 allowed	 to	 translate	 and	 rotate	 over	
10000	 iterations	 to	 find	 the	 correct	minimum.	The	model	 for	
the	 SPN-phenol	 cocrystal	 structure	 was	 refined	 using	 the	
Rietveld	and	converged	to	χ2	=	7.210.	For	 the	SPN-2,5-xylenol	
cocrystal,	the	Rietveld	refinement	converged	χ2	=	6.115.	Figure	
S2	 and	 S3	 of	 the	 supplementary	 information	 depict	 the	 final	
Rietveld	 plots	 for	 the	 SPN-phenol	 and	 SPN-2,5-xylenol	
cocrystals	respectively.	
Results	and	Discussion	
A	database	of	310	CCFs	was	used	to	calculate	a	hierarchical	list	
based	on	the	stability	of	the	potential	GSF	and	SPN	cocrystals	
compared	 to	 the	 sum	 of	 the	 two	 pure	 components	 (ΔE	
expressed	in	kJ	mol-1).	For	a	list	of	all	the	310	CCFs	used,	please	
see	the	Supporting	Information.	Table	1	shows	the	top	35	CCFs	
that	are	predicted	most	likely	to	yield	cocrystals	with	GSF	and	
SPN	 along	with	 their	 corresponding	 ΔE	 values.	 Both	 GSF	 and	
SPN	 are	 predicted	 to	 form	 favourable	 interactions	with	 good	
H-bond	donors	such	as	carboxylic	acids	and	phenols,	because	
they	 have	 carbonyl	 groups	 that	 can	 act	 as	 H-bond	 acceptors	
and	 no	 H-bond	 donors.	 GSF	 was	 subjected	 to	 experimental	
screening	with	the	CCFs	from	the	left	side	of	Table	1	while	SPN	
was	tested	with	the	right-hand	side	CCFs.	Just	over	10%	of	the	
CCF	 database	 with	 ΔE	 values	 greater	 than	 10	 kJ	 mol-1	 was	
therefore	screened	for	each	API.	
	
Figure	 1.	 Chemical	 structures	 of	 GSF,	 SPN	 and	 the	 CCFs	 that	 formed	 cocrystals	 as	
judged	by	XRPD.	
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Table	1.	Top	ranked	CCFs	based	on	∆E.	
Griseofulvin	(GSF)	 	 Spironolactone	(SPN)	 	
CCF	 ΔΕ	/	kJ	mol-1	 CCF	 ΔΕ	/	kJ	mol-1	
3,4-dihydroxybenzoic	acid	 28.3	 3,4-dihydroxybenzoic	acid	 26.8	
Etidronic	acid	 27.2	 Resorcinol	 25.8	
Resorcinol	 26.2	 Etidronic	acid	 24.6	
Citric	acid	 22.8	 Sucralose	 22.0	
Tartaric	acid	 22.5	 Tartaric	acid	 20.1	
Camphoric	acid	 22.2	 Citric	acid	 19.5	
Malonic	acid	 21.7	 Propyl	gallate	 18.4	
Propyl	gallate	 20.6	 Tert-butylhydroquinone	 17.7	
Sucralose	 20.2	 Malic	acid	 17.1	
Malic	acid	 20.0	 Oxalic	acid	 16.6	
Oxalic	acid	 19.3	 3-hydroxybenzoic	acid	 16.3	
Tert-butylhydroquinone	 18.9	 4-hydroxybenzoic	acid	 16.2	
2,5-dihydroxybenzoic	acid	 18.4	 Fumaric	acid	 16.1	
3-hydroxybenzoic	acid	 17.8	 2,5-dihydroxybenzoic	acid	 15.5	
4-hydroxybenzoic	acid	 17.7	 L-rhamnose	 15.0	
L-rhamnose	 16.7	 Sucrose	 14.6	
Succinic	acid	 15.7	 Maltose	 14.3	
Thiodipropionic	acid	 15.4	 L-tyrosine	 13.8	
Ascorbic	acid	 14.7	 Succinic	acid	 12.8	
L-tyrosine	 14.6	 Thymol	 12.7	
Sucrose	 14.5	 Thiodipropionic	acid	 12.6	
Maltose	 14.2	 2-phenyl	phenol	 12.5	
L-glutamic	acid	 14.0	 Ascorbic	acid	 12.5	
Adipic	acid	 13.5	 Urea	 12.5	
Folic	acid	 12.8	 2,4-dihydroxybenzoic		acid	 12.5	
Taurine	 12.2	 L-glutamic	acid	 12.4	
1-hydroxy-2-naphthoic	acid	 11.8	 Butylated	hydroxytoluene	 11.8	
2,5-xylenol	 11.4	 1-hydroxy-2-naphthoic	acid	 11.5	
2-phenyl	phenol	 11.4	 2,5-xylenol	 11.4	
4-tert-butylphenol	 11.1	 Taurine	 11.3	
Pyridoxine	 11.1	 Adipic	acid	 11.3	
Skatole	 10.7	 4-tert-butylphenol	 11.0	
D-isoascorbic	acid	 10.6	 3,4-xylenol	 10.4	
Phenol	 10.5	 Phenol	 10.1	
D-ribose	 10.5	 Folic	acid	 9.8	
	
	
Table	2.		Crystallographic	data	for	griseofulvin	and	spironolactone	cocrystals.	
	 GSF	–	4-tert-butylphenol	 SPN-phenol		 SPN-2,5-xylenol	
Stoichiometry	 1:1	 1:1	 1:1	
crystal	system	 Monoclinic	 Orthorhombic	 Monoclinic	
space	group	 P21	 P212121	 P21	
a	(Å)	 13.10068	(14)	 18.5914(4)	 24.7971(6)	
b	(Å)	 8.65708	(10)	 22.6434(5)	 10.2080(3)	
c	(Å)	 11.62420	(15)	 6.4703(2)	 6.3069(1)	
α	(°)	 90	 90	 90	
β	(°)	 98.9448	(8)	 90	 112.538(2)	
γ	(°)	 90	 90	 90	
Z	 2		 2	 2	
V	(Å3)	 1302.31	 2723.8(1)	 1474.52(6)	
Indices	of	fit	 χ2	=	6.212	 χ2	=	7.210	 χ2	=	6.115	
CCDC	 1517121	 1517122	 1517123	
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Experimental	cocrystal	screen	
Liquid-assisted	grinding	(LAG)	was	the	experimental	method	of	
choice	due	to	efficiency	and	speed.	The	chemical	structures	of	
the	 two	 APIs	 and	 the	 CCFs	 that	 led	 to	 successful	
cocrystallisation	by	this	method	are	shown	in	Figure	1.	
Griseofulvin	
Cocrystal	 formation	 was	 initially	 studied	 by	 LAG	 of	 1:1	
stoichiometric	ratios	of	GSF	with	the	corresponding	CCFs	using	
n-heptane	as	a	catalytic	solvent.	This	solvent	does	not	readily	
form	 solvates	 with	 small	 organic	 molecules	 and	 minimises	
sample	dissolution	due	 to	 the	 low	polarity.	The	LAG	mixtures	
were	analysed	by	XRPD	to	identify	the	form	and	crystallinity	of	
the	 samples.	 A	 system	 was	 defined	 as	 a	 hit	 if,	 following	
grinding,	 it	displayed	a	different	powder	pattern	compared	to	
the	 patterns	 of	 the	 two	 pure	 components.	 Analysis	 of	 the	
XRPD	 patterns	 revealed	 that	 physical	 mixtures	 of	 the	
components	 or	 peaks	 corresponding	 to	 pure	 GSF	 were	
obtained	in	most	cases	(data	not	shown).	The	grinding	of	a	1:1	
GSF	 and	 4-tert-butylphenol	 mixture	 for	 45	 minutes	 at	 30	 Hz	
gave	 a	 powder	 pattern	 different	 from	 the	 pure	 components	
but	 the	 crystallinity	of	 the	 sample	was	poor.	Acetonitrile	was	
tried	 as	 an	 alternative	 LAG	 solvent	 under	 the	 same	 grinding	
conditions	and	a	highly	crystalline	phase	was	obtained	(Figure	
2a,	green	trace).	
	
Figure	 2.	 XRPD	 patterns	 of	 (a)	 griseofulvin	 (blue),	 4-tert	 butylphenol	 (red)	 and	 a	 1:1	
mixture	 after	 LAG	 (green);	 (b)	 spironolactone	 (blue),	 phenol	 (red)	 and	 a	 1:1	mixture	
after	 LAG	 (green);	 (c)	 spironolactone	 (blue),	 2,5-xylenol	 (red)	 and	 a	 1:1	mixture	 after	
LAG	(green).	
Furthermore,	the	reflections	arising	from	the	starting	materials	
were	 absent,	 suggesting	 that	 a	 new	 pure	 phase	 has	 been	
obtained.	 The	 new	 XRPD	 pattern	 was	 compared	 to	 the	
calculated	XRPD	pattern	of	a	GSF-acetonitrile	solvate	that	has	
been	 previously	 discovered	 (CCDC	 refcode	 PINMOQ)	 35.	 The	
powder	pattern	obtained	from	the	crystal	structure	of	the	GSF-
acetonitrile	solvate	was	completely	different	 from	that	of	 the	
one	 obtained	 following	 the	 LAG	 mixture	 of	 GSF	 and	 4-tert-
butylphenol.		
The	thermal	stability	of	this	sample	was	also	analysed	by	DSC	
(Figure	3a).	The	endothermic	peaks	that	do	not	correspond	to	
the	melting	points	of	the	pure	components	suggest	a	cocrystal.	
The	thermogram	shows	a	single	sharp	endotherm	with	melting	
onset	at	151.5°C	and	a	peak	at	153.4°C,	which	is	between	the	
melting	 points	 of	 GSF	 (220.2°C)	 and	 4-tert-butylphenol	
(100.0°C).	 This	 observation	 is	 consistent	with	 the	majority	 of	
previously	reported	cocrystals.51	
	
Figure	 3.	 DSC	 traces	 of	 (a)	 griseofulvin	 (blue),	 4-tert-butylphenol	 (red)	 and	 the	 1:1	
griseofulvin-4-tert-butylphenol	cocrystal	(green);	(b)	spironolactone	(blue),	phenol	(red)	
and	 the	 1:1	 spironolactone-phenol	 	 cocrystal	 (green);	 (c)	 spironolactone	 (blue),	 2,5-
xylenol	(red)	and	the	1:1	spironolactone-2,5-xylenol		cocrystal	(green).	
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Figure	4.	TGA	traces	of	(a)	the	1:1	griseofulvin-4-tert-butylphenol	cocrystal;	(b)	the	1:1	
spironolactone-phenol	cocrystal	and	(c)	the	1:1	spironolactone-2,5-xylenol		cocrystal.	
Weight	loss	from	the	cocrystal	sample	on	heating	was	studied	
by	 TGA	 (Figure	 4a).	 The	 observed	 weight	 loss	 of	 29.5%	
corresponds	 to	 the	 evaporation	 or	 sublimation	 of	 4-tert-
butylphenol	 from	 a	 1:1	 cocrystal	 (theoretically	 29.8%	 of	 the	
overall	molecular	weight).	There	is	a	single	melting	endotherm	
observed	 during	 the	 heating	 process	 of	 the	 cocrystal	 at	
approximately	 153°C.	 It	 is	 likely	 that	 under	 the	 sealed-pan	
conditions	 of	 the	 DSC	 experiment,	 melting	 of	 the	 cocrystal	
occurs	 at	 a	 lower	 temperature	 than	 the	 loss	 of	 4-tert-
butylphenol.	 In	 the	 open-pan	 TGA	 experiment,	 the	 CCF	 loss	
can	 occur	 at	 a	 temperature	 below	 the	 melting	 point	 of	 the	
cocrystal.	 	 Although	 the	 TGA	 temperature	 range	 is	
considerably	lower	than	the	boiling	point	of	4-tert-butylphenol	
(237°C),52	 sublimation	 at	 a	 lower	 temperature	 has	 been	
reported	previously	for	cocrystals.53	
The	 new	 phase	 was	 analyzed	 by	 solid-state	 infrared	
spectroscopy	 (IR).	 Changes	 in	 the	 IR	 spectrum	 are	 consistent	
with	different	 intermolecular	 interactions	 in	 the	mixed	phase	
compared	 with	 the	 pure	 components	 (Figure	 S4,	 Appendix).	
For	example,	the	OH	stretch	at	3224	cm-1	in	4-tert-butylphenol	
is	shifted	to	3279	cm-1	in	the	new	phase.		
The	crystal	structure	of	the	cocrystal	was	determined	from	the	
XRPD	pattern.	The	GSF:4-tert-butylphenol	cocrystal	crystallizes	
in	 the	 monoclinic	 system	 with	 space	 group	 P21	 and	 one	
molecule	 of	 each	 component	 in	 the	 asymmetric	 unit.	
Molecules	 of	 GSF	 interact	 through	 C–Cl···O	 halogen	 bonds	
creating	 chains	 parallel	 to	 the	 crystallographic	 21	 screw	 axis	
(O3···Cl	3.23	Å,	O4···Cl	3.22	Å).	The	main	interaction	leading	to	
cocrystal	 formation	 is	 a	 H-bond	 between	 the	 4-tert-
butylphenol	 H-bond	 donor	 and	 the	 cyclohexenone	 carbonyl	
group	(Figure	5a).	
	
Figure	 5.	 Crystal	 structures	 of	 (a)	 the	 1:1	 griseofulvin-4-tert-butylphenol	 cocrystal	
[d(O1-O2)	 =	 2.545	 Å,	 d(O3-Cl)	 =	 3.231	 Å),	 d(O4-Cl)	 =	 3.216	 Å)],	 (b)	 the	 1:1	
spironolactone-phenol	cocrystal	 [d(O1-O2)	=	2.767	Å)]	and	(c)	the	1:1	spironolactone-
2,5-xylenol	cocrystal	[d(O1-O2)	=	2.891	Å].	The	black	dotted	lines	represent	H-bonds.	
Spironolactone	
LAG	 experiments	 were	 initially	 carried	 out	 for	 1:1	
stoichiometric	 ratios	 of	 SPN	 to	 CCFs	 in	 the	 presence	 of	 n-
heptane	for	45	minutes	at	30	Hz.	This	led	to	amorphisation	as	
indicated	by	a	reduction	in	intensity	and	sharpness	of	the	X-ray	
reflections	 after	 grinding.	 To	 reduce	 the	 energy	 input,	 the	
grinding	time	was	reduced	to	25	minutes.	Novel	XRPD	patterns	
were	 obtained	 on	 grinding	 SPN	 with	 CCFs	 2,5-
dihydroxybenzoic	 acid,	 2,5-xylenol	 and	 phenol.	 The	 SPN-2,5-
dihydroxybenzoic	acid	XRPD	pattern	was	already	reported	in	a	
previous	study,38	therefore	no	further	work	was	carried	out	on	
this	 system.	 The	 SPN-2,5-xylenol	 and	 SPN-phenol	 materials	
obtained	were	highly	crystalline	(green	traces	in	Figures	2b	and	
2c,	 respectively)	 and	 established	 as	 phase	 pure	 by	 Pawley	
fitting	of	the	patterns.	
DSC	 experiments	 for	 both	 new	 forms	 showed	 a	 sharp,	 single	
melting	endotherm	with	a	melting	point	between	those	of	the	
starting	materials,	 further	suggesting	cocrystal	 formation.	The	
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SPN-phenol	 system	 has	 a	 melting	 onset	 at	 110.0°C	 (peak	 at	
112.3°C,	 Figure	 3b	 green	 trace),	 while	 the	 SPN-2,5-xylenol	
material	has	a	melting	onset	at	95.4°C	(peak	at	96.9°C,	Figure	
3c	green	trace).	
TGA	of	the	SPN-phenol	cocrystal	showed	a	steady	weight	 loss	
starting	 at	 the	 beginning	 of	 the	 heating	 process	 and	 still	
occurring	at	225°C.	The	early	change	in	the	sample	mass	could	
be	 caused	 by	 the	 volatile	 nature	 of	 phenol,	 while	 further	
weight	loss	at	high	temperatures	is	most	likely	due	to	chemical	
degradation	of	the	compound.	In	the	TGA	trace	of	the	SPN-2,5-
xylenol	cocrystal,	 two	events	were	observed:	a	weight	 loss	of	
15.4%	between	83.2°C	and	116.4°C,	 followed	by	another	 loss	
of	7.8%	between	179.2°C	and	205.9°C.	The	total	weight	loss	of	
23.2%	can	be	assigned	to	the	loss	of	1	molecule	of	2,5-xylenol.	
There	are	also	obvious	differences	between	 the	 IR	 spectra	of	
the	mixtures	and	those	of	the	pure	solids	observed	for	both	of	
these	systems	(Figure	S5	and	S6,	Appendix).	
Crystal	structures	of	the	cocrystals	were	determined	from	the	
XRPD	patterns.	The	SPN-phenol	cocrystal	has	an	orthorhombic	
cell	 with	 space	 group	 P212121	 and	 one	 molecule	 of	 each	
component	in	the	asymmetric	unit.	The	phenol	group	forms	H-
bonds	 as	 a	 donor	 with	 the	 cyclohexanone	 carbonyl	 group	
(Figure	5b).	The	SPN-2,5-xylenol	cocrystal	has	a	monoclinic	cell	
with	space	group	P21	and	one	molecule	of	each	component	in	
the	 asymmetric	 unit.	 Molecules	 of	 SPN	 interact	 with	 2,5-
xylenol	molecules	through	H-bonds	between	the	phenol	donor	
and	the	furanone	acceptor	(Figure	5c).	
	
Conclusions	
Based	on	 a	 virtual	 screening	method	 for	 cocrystal	 prediction,	
an	experimental	strategy	was	designed	and	applied	to	discover	
novel	 cocrystals	 of	 two	 non-ionisable	 APIs	 of	 low	 aqueous	
solubility,	GSF	and	SPN.	The	computational	tool	compares	the	
stability	 of	 a	 cocrystal	 to	 the	 two	 components	 using	 SSIPs	 to	
calculate	 the	 difference	 in	 the	 solid	 state	 interaction	 site	
pairing	 energies	 (∆E).	 A	 database	 of	 310	 potential	 CCFs	 was	
screened	 using	 this	 approach,	 and	 the	 35	 CCFs	 that	 showed	
the	 highest	 values	 of	 ∆E	 were	 subjected	 to	 experimental	
investigation	using	 liquid-assisted	 grinding.	One	GSF	 cocrystal	
and	 two	 SPN	 cocrystals	 were	 identified,	 and	 the	 crystal	
structures	 of	 the	 cocrystals	 were	 determined	 from	 the	 X-ray	
powder	 diffraction	 patterns.	 The	 cocrystals	 were	 further	
analysed	 by	 DSC,	 TGA	 and	 IR.	 Although	 the	 identification	 of	
three	 cocrystals	 after	 screening	 70	 CCFs	 could	 be	 seen	 as	 a	
modest	 success	 rate,	 this	 study	 demonstrates	 that	
computational	 prediction	 can	 be	 successfully	 applied	 to	 APIs	
where	 cocrystal	 design	 is	 difficult	 due	 to	 limited	 H-bonding	
potential.	
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